NCT02209792View on ClinicalTrials.gov

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

January 31, 2004

Conditions
Crohn Disease
Interventions
DRUG

Placebo

DRUG

BIBR 796 BS, 5 mg

DRUG

BIBR 796 BS, 20 mg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02209792 - Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter